On the fly News and insights, exclusive to thefly.com

ESPR

Esperion

$59.05 /

-9.23 (-13.52%)

15:03
02/21/20
02/21
15:03
02/21/20
15:03

Esperion selloff on Nexletol approval attributed to adverse event profile

The selloff in shares of Esperion Therapeutics following news of the FDA approving its cholesterol treatment Nexletol is being attributed to the concerns over the drug's adverse event profile. CNCB's Meg Tirrell tweeted, "$ESPR drug approved, stock drops 7% - Jefferies' @therealJHOLZ cites investor concern about adverse event profile." Shares of Esperion are down 7%, or $4.78, to $63.57 in afternoon trading.

  • 21

    Feb

  • 26

    Feb

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.